AVTR — Avantor, Inc.
Is AVTR overbought or oversold? Here is the current MarketMoodz read.
Avantor, Inc. (AVTR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $15.18. The rating moved from Strong Oversold to Oversold on November 9, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$15.18
- Last changeMoved from Strong Oversold to Oversold on November 9, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
See all oversold Healthcare stocks →
AI analysis
Avantor is well exposed to secular growth in biopharma and specialty-care distribution, with recurring consumables and services supporting revenue visibility. Near-term catalysts include continued adoption of specialty injectables and stability in large-cap pharma spending, while margin improvement depends on successful operational execution and cost control. Key downside drivers are cyclical demand swings, competitive pricing pressure, and regulatory or supply-chain shocks that could impair near-term cash flow and profitability.
Key factors
- Positioned as a leading supplier to life-sciences, biopharma and specialty-care channels; benefits from secular growth in biologics, personalized medicine and chronic injectable therapies that drive consumables and services demand.
- Distributor shift to specialty care and infusion/biopharma services supports sustained volume and higher-margin services demand for lab/distribution partners.
- Recurring-revenue components (consumables, reagents, service contracts) provide revenue visibility and resilience versus one-time capital sales.
- Operational improvement initiatives and scale economics can drive margin expansion if execution continues and industrial cost pressures moderate.
- Measured market risk-on tone and sector flows into healthcare and large-cap pharma provide a favorable sentiment backdrop for distributors tied to drug manufacturing.
- Relative valuation appears constructive versus large-cap peers, offering upside if growth and margin recovery continue.
Risks
- Cyclical end-market exposure (pharma R&D and industrial customers) could lead to demand volatility and inventory destocking.
- Intense competition from larger integrated players and distributor peers may pressure pricing and margins.
- Execution risk on operational improvement programs; failure to execute could delay expected margin gains.
- Regulatory and compliance changes in healthcare/pharma distribution could increase costs or restrict certain revenue streams.
- Foreign-exchange, raw-material cost pass-through limitations, and supply-chain disruptions could compress profitability.
- Leverage and refinancing risk if balance-sheet flexibility is overstated or credit markets tighten (company-level financials not provided here).
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for AVTR — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.